Posted by Michael Wonder on 30 Sep 2019
Health Canada approves Dupixent as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis
27 September 2019 - Dupixent can significantly reduce the constant itch and improve the skin's overall condition.
Health Canada has approved Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescent patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Treatment with Dupixent, the first targeted therapy for moderate-to-severe AD, demonstrated a significant improvement in the signs and symptoms of the condition and certain quality of life measures in adolescent patients.
The adolescent indication for Dupixent is based on the findings from a pivotal Phase 3 trial presented at the 27th European Academy of Dermatology and Venereology Congress in Paris, France in 2018.
